Tech Company Financing Transactions
Avenue Biosciences Funding Round
Voima Ventures, Inventure and private investors participated in a $2.5 million Seed venture round for Avenue Biosciences. The funding round was announced on 10/22/2024.
Transaction Overview
Company Name
Announced On
10/22/2024
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Seed
Investors
Voima Ventures (Lead Investor) (Jenny Engerfelt)
Inventure (Tuomas Kosonen)
Proceeds Purpose
The funding will accelerate the development of Avenue Biosciences platform, designed to improve the efficiency of protein production in the biopharmaceutical industry.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Viikinkaari 1A
Helsinki, 00790
Finland
Helsinki, 00790
Finland
Phone
Undisclosed
Website
Email Address
Overview
Proteins are foundational to therapeutic discovery and human health. The use of machine learning and artificial intelligence is set to revolutionize the development of protein biologics and tools for biotechnology processes. A unique high throughput chemistry combined with our software platform are now opening a new dimension for the industry.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tero-Pekka Alastalo
Chief Operating Officer
Katja Rosti
Chief Scientific Officer
Juho Kellosalo
Chief Scientific Officer
Anton Klåvus
VP - Marketing
Juulia Simonen
Browse more venture capital transactions:
Prev: 10/22/2024: NEPC venture capital transaction
Next: 10/22/2024: Reality Defender venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs